Pliant Therapeutics Inc
Pliant Therapeutics Inc (PLRX) Option Chain
As of October 5, 2026, Pliant Therapeutics Inc is trading at $1.02, a -0.98% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 307.7%. IV Rank is 71%.
Read more
Tracking the PLRX option chain helps you see every strike and expiry on Pliant Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Pliant Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of PLRX options activity at a glance. Use our scanner to monitor the PLRX option chain in real time and filter for the PLRX options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For PLRX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the PLRX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where PLRX stock options are being actively traded and where they are not.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Pliant Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen PLRX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of PLRX stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile70.63% Elevated
- Market cap (M$)64
- 52 weeks high-47.18%
- 52 weeks low0.98%
- Analyst recommendationSell
3.50 - Target price$1.51
48.04% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.50
- EPS growth next 5 years23.86%
As of October 5, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 13.35 | 3 | 0 | 0.08 | 0.52 | 0.10 | 1.10 | 0.50 | -51.46 | — | 0.05 | 0.00 | 0.05 | 0 | 50 | 86.65 |
| 58.13 | 204 | 0 | 0.98 | 0.02 | — | 1.00 | 1.00 | -2.91 | — | 0.10 | 0.00 | 0.10 | 70 | 2,235 | 41.87 |
| 83.51 | 11 | 0 | 0.05 | 0.00 | — | 0.05 | 1.50 | +45.63 | 0.10 | 1.10 | 0.48 | 0.12 | 0 | 0 | 16.49 |
| 93.58 | 5 | 0 | 0.05 | 0.00 | — | 0.05 | 2.00 | +94.17 | 0.50 | 1.50 | 0.98 | 0.02 | 0 | 0 | 6.42 |
| 97.40 | 36 | 0 | 0.05 | 0.00 | — | 0.05 | 2.50 | +142.72 | 1.00 | 2.00 | 1.48 | 0.02 | 0 | 0 | 2.60 |
As of October 5, 2026
Scan the full option chain in one place
Browse the full PLRX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→